Compare Biogen Inc (BIIB) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Invesco DB Commodity Index Tracking Fund trades at $29.94. Which is the better fit depends on your goals.
| BIIB | DBC | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $31.69 |
52-Week Low | $128.93 | $21.62 |
Enterprise Value | $37.20B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
